The Mirati Therapeutics ticker is MRTX and it is traded on the NASDAQ.

In June 2013, Mirati Therapeutics, Inc. became the ultimate parent corporation of MethylGene Inc. and subsidiaries by a court and shareholder-approved plan of arrangement. Mirati shares began trading on the NASDAQ on July 15, 2013.

9363 Towne Centre Drive, Suite 200
San Diego, CA 92121

You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.

You can view our management team by visiting the Management section of our Investor Relations website.

December 31

Ernst & Young LLP

Mirati Therapeutics does not expect to declare or pay any cash or other dividends on our common stock, as we intend to reinvest cash flow generated by operations in our business.

Mirati Therapeutics does not currently have a direct stock purchase plan.

Quarterly and annual reports, as well as other SEC, can be accessed on the Financial Information portion of our Investor Relations website or directly from the SEC at http://www.sec.gov/.  Note that in June 2013, Mirati Therapeutics, Inc. became the ultimate parent corporation of MethylGene Inc. and subsidiaries by a court and shareholder-approved plan of arrangement.

You can contact Mirati Therapeutics Investor Relations via email at:

ir@mirati.com

In addition, you can reach Investor Relations by calling 858.332.3410. 

Please submit your question using the form below.

Contact Form
* Indicates required field
http://apps.shareholder.com/captcha/captcha.aspx?verifyid=1857558101&CompanyID=AMDA-203FQQ&t=.jpg